2019
DOI: 10.1007/s10571-019-00758-5
|View full text |Cite
|
Sign up to set email alerts
|

Gracilin-Derivatives as Lead Compounds for Anti-inflammatory Effects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
40
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 13 publications
(41 citation statements)
references
References 43 publications
1
40
0
Order By: Relevance
“…In the following experiments, the concentration of 1 μM of GraL, 0.1 μM of compounds 1 and 2 , and 0.2 μM of CsA were used. Since these concentrations have shown the greatest anti-inflammatory activity without compromising cell viability in previous experiments, both in T lymphocytes and glial cells ( 20 , 21 , 25 ). As shown in Figure 3A , the liberation of CypA was significantly reduced, when T cells were preincubated with compound 1 ( p < 0.05), compound 2 ( p < 0.05) or GraL ( p < 0.001).…”
Section: Resultsmentioning
confidence: 77%
See 3 more Smart Citations
“…In the following experiments, the concentration of 1 μM of GraL, 0.1 μM of compounds 1 and 2 , and 0.2 μM of CsA were used. Since these concentrations have shown the greatest anti-inflammatory activity without compromising cell viability in previous experiments, both in T lymphocytes and glial cells ( 20 , 21 , 25 ). As shown in Figure 3A , the liberation of CypA was significantly reduced, when T cells were preincubated with compound 1 ( p < 0.05), compound 2 ( p < 0.05) or GraL ( p < 0.001).…”
Section: Resultsmentioning
confidence: 77%
“…Besides, they can modify transcriptional factors and reduce IL-2 release in activated T cells by blocking the activity of calcineurin phosphatase and inhibit CypA release ( 20 , 22 , 27 ). Moreover, it was recently reported that synthetic GraA-derivatives reduce the release of inflammatory mediators, avoid the translocation to the nucleus of inflammatory target proteins and promote antioxidative mechanisms in activated BV2 cells, likely through the CypA modulation ( 25 ). In the present paper, GraL and two GraA-derivatives, compounds 1 and 2 , with high CypA affinity, in the CsA range, were chosen.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…A “lead compound”’ is defined as a chemical entity that has newly discovered promising therapeutic activity and into which further chemical modifications can be introduced to develop a new compound with optimized beneficial effects and minimized side effects [ 1 ]. Lead compounds have been used to develop new antimalarial [ 2 , 3 ], anti-inflammatory [ 4 , 5 ], anticancer [ 6 , 7 , 8 ], anti-platelet [ 9 , 10 , 11 ], and anticoagulant [ 12 , 13 ] agents. To transform these compounds for use as drug candidates in clinical trials, a number of requirements, such as stability, production with cGMP (current good manufacturing processes), identification of metabolic pathways and potential drug–drug interactions, toxicology assessments, and clinical development plans, must be met to establish a model pathway of drug development [ 14 ].…”
Section: Introductionmentioning
confidence: 99%